IL289166A - Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use - Google Patents
Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their useInfo
- Publication number
- IL289166A IL289166A IL289166A IL28916621A IL289166A IL 289166 A IL289166 A IL 289166A IL 289166 A IL289166 A IL 289166A IL 28916621 A IL28916621 A IL 28916621A IL 289166 A IL289166 A IL 289166A
- Authority
- IL
- Israel
- Prior art keywords
- lrrc25
- compositions
- methods
- myeloid cell
- cell inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867593P | 2019-06-27 | 2019-06-27 | |
PCT/US2020/038115 WO2020263650A1 (en) | 2019-06-27 | 2020-06-17 | Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL289166A true IL289166A (en) | 2022-02-01 |
Family
ID=74060354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL289166A IL289166A (en) | 2019-06-27 | 2021-12-20 | Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220363752A1 (zh) |
EP (1) | EP3990017A4 (zh) |
JP (1) | JP2022539038A (zh) |
KR (1) | KR20220042131A (zh) |
CN (1) | CN114423452A (zh) |
AU (1) | AU2020306772A1 (zh) |
BR (1) | BR112021026411A2 (zh) |
CA (1) | CA3142838A1 (zh) |
IL (1) | IL289166A (zh) |
WO (1) | WO2020263650A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024077170A1 (en) * | 2022-10-05 | 2024-04-11 | Shangpharma Innovation, Inc. | Anti-urokinase-type plasminogen activator receptor antibodies and methods of use |
CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10279018B2 (en) * | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
EP3311173A2 (en) * | 2015-06-18 | 2018-04-25 | Thomas Mole Herd | Methods of characterising cancer |
WO2017004153A1 (en) * | 2015-06-29 | 2017-01-05 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
BR112018076005A2 (pt) * | 2016-06-14 | 2019-03-26 | Advanced Biodesign | anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral |
CA3030841A1 (en) * | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
TW202023629A (zh) * | 2018-06-29 | 2020-07-01 | 美商維西歐製藥公司 | 用於調節單核球及巨噬細胞發炎表型之組合物及方法以及其免疫療法用途 |
-
2020
- 2020-06-17 WO PCT/US2020/038115 patent/WO2020263650A1/en active Application Filing
- 2020-06-17 US US17/620,264 patent/US20220363752A1/en active Pending
- 2020-06-17 AU AU2020306772A patent/AU2020306772A1/en active Pending
- 2020-06-17 CA CA3142838A patent/CA3142838A1/en active Pending
- 2020-06-17 EP EP20833200.7A patent/EP3990017A4/en not_active Withdrawn
- 2020-06-17 BR BR112021026411A patent/BR112021026411A2/pt unknown
- 2020-06-17 JP JP2021576604A patent/JP2022539038A/ja active Pending
- 2020-06-17 CN CN202080061285.3A patent/CN114423452A/zh active Pending
- 2020-06-17 KR KR1020227003081A patent/KR20220042131A/ko unknown
-
2021
- 2021-12-20 IL IL289166A patent/IL289166A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3142838A1 (en) | 2020-12-30 |
US20220363752A1 (en) | 2022-11-17 |
CN114423452A (zh) | 2022-04-29 |
KR20220042131A (ko) | 2022-04-04 |
EP3990017A1 (en) | 2022-05-04 |
EP3990017A4 (en) | 2023-04-26 |
AU2020306772A1 (en) | 2022-02-17 |
BR112021026411A2 (pt) | 2022-03-15 |
WO2020263650A1 (en) | 2020-12-30 |
JP2022539038A (ja) | 2022-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282735A (en) | Preparations and methods for t-cell engineering | |
IL288511A (en) | Anti-siglec-9 preparations and methods for modulating inflammatory myeloid cell phenotypes and uses thereof | |
IL277079A (en) | Cartirin preparations and methods of use | |
IL275263A (en) | Preparations and methods for inhibiting T cell exhaustion | |
EP3701041A4 (en) | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH DEPLETED T-LYMPHOCYTES | |
SG11202004116QA (en) | T cell manufacturing compositions and methods | |
IL269334A (en) | Improved compositions of t cells and methods | |
IL268058B1 (en) | Compositions and methods for depleting cd137 plus cells | |
IL286776A (en) | Preparations and methods for preparing t cell preparations and their uses | |
IL282447A (en) | Methods and preparations for healing eye cell | |
IL291622A (en) | Compositions comprising regulatory t cells and methods of making and using them | |
IL287874A (en) | Preparations and methods for producing t cells | |
IL289166A (en) | Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use | |
IL289171A (en) | Anti-cd53 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use | |
GB202208953D0 (en) | Therapeutic cell compositions and methods for manufacture and uses thereof | |
IL282160A (en) | Preparations and methods for transferring genes between cells | |
EP3813856A4 (en) | CELL COMPOSITIONS AND USES THEREOF | |
IL288510A (en) | Anti-psgl-1 preparations and methods for modulating inflammatory myeloid cell phenotypes and uses thereof | |
IL284327A (en) | Compounds and Methods for Inhibiting Expression of HMGB1 | |
IL280330A (en) | Preparations and methods related to agriculture | |
IL277878A (en) | Preparations and methods for stem cell transplantation | |
IL282914A (en) | T cell preparations with improved phenotypic characteristics | |
EP3810152A4 (en) | CELLULAR PROTECTION METHODS AND COMPOSITIONS | |
FI3899996T3 (fi) | Elektrolyyttikompositioita | |
IL290325A (en) | Biopharmaceutical preparations and related methods |